This paper forms part of the supplement entitled ‘Update on endothelin-related diseases’. It is related to discussions at the workshop ‘Endothelin-related diseases’ at 42nd Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI) in Geneva, Switzerland, 26–29 March 2008. The workshop and the production costs of the present supplement were supported with an unrestricted Educational Grant from Encysive Pharmaceuticals Inc. In June 2008, Encysive was acquired by Pfizer Inc who funded the publication and formatting costs of this supplement. Diane Warner and Tracy Johnson formatted the manuscript according to the journal’s style requirements.
Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence
Version of Record online: 24 MAR 2009
© 2009 The Authors. Journal Compilation © 2009 Blackwell Publishing Ltd
European Journal of Clinical Investigation
Special Issue: Update on endothelin-related diseases
Volume 39, Issue Supplement s2, pages 50–67, June 2009
How to Cite
Neuhofer, W. and Pittrow, D. (2009), Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. European Journal of Clinical Investigation, 39: 50–67. doi: 10.1111/j.1365-2362.2009.02121.x
- Issue online: 24 MAR 2009
- Version of Record online: 24 MAR 2009
- Received 1 August 2008; accepted 3 February 2009
- Chronic kidney disease;
- endothelin receptor antagonist;
Endothelin (ET) is a potent vasoconstrictory peptide with proinflammatory and profibrotic properties that exerts its biological effects through two pharmacologically distinct receptor subtypes, namely ETA and ETB. In addition to its substantial contribution to normal renal function, a large body of evidence suggests that derangement of the renal ET system is involved in the initiation and progression of chronic kidney disease (CKD) in diabetes, hypertension and glomerulonephritis. Thus, the use of ET receptor antagonists (ERAs) may offer potential novel treatment strategies in CKD. Recent literature on the role of the renal ET system in the healthy kidney was reviewed. In addition, an unbiased PubMed search was performed for studies published during the last 5 years that addressed the effects of ERAs in CKD. A particular objective was to extract information regarding whether selective or nonselective ERAs may have therapeutic potential in humans. ET-1 acts primarily as an autocrine or paracrine factor in the kidney. In normal physiology, ET-1 promotes diuresis and natriuresis by local production and action through ETB receptors in the renal medulla. In pathology, ET-1 mediates vasoconstriction, mesangial-cell proliferation, extracellular matrix production and inflammation, effects that are primarily conveyed by ETA receptors. Results obtained in animal models and in humans with the use of ERAs in CKD are encouraging; nevertheless, it is still under debate which receptor subtype should be targeted. According to most studies, selective inhibition of ETA receptors appears superior compared with nonselective ERAs because this approach does not interfere with the natriuretic, antihypertensive and ET clearance effects of ETB receptors. Although preliminary data in humans are promising, the potential role of ERAs in patients with CKD and the question of which receptor subtype should be targeted can only be clarified in randomized clinical trials.